WO2016103699A1 - Promoteur de production d'acides organiques, et agent pour prévenir et/ou améliorer une maladie intestinale inflammatoire - Google Patents

Promoteur de production d'acides organiques, et agent pour prévenir et/ou améliorer une maladie intestinale inflammatoire Download PDF

Info

Publication number
WO2016103699A1
WO2016103699A1 PCT/JP2015/006425 JP2015006425W WO2016103699A1 WO 2016103699 A1 WO2016103699 A1 WO 2016103699A1 JP 2015006425 W JP2015006425 W JP 2015006425W WO 2016103699 A1 WO2016103699 A1 WO 2016103699A1
Authority
WO
WIPO (PCT)
Prior art keywords
organic acid
production promoter
lactic acid
bifidobacteria
acid production
Prior art date
Application number
PCT/JP2015/006425
Other languages
English (en)
Japanese (ja)
Inventor
明 田村
みどり 夏目
球一 川畑
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to JP2016565924A priority Critical patent/JP6810610B2/ja
Publication of WO2016103699A1 publication Critical patent/WO2016103699A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the lactic acid bacterium is not particularly limited, but a lactic acid bacterium belonging to the genus Lactobacillus which is a Gram-positive rod is preferable.
  • Bulgaricus is preferable, and specifically, Lactobacillus delbrueckii subsp.
  • Bulgaricus OLL1181 (FERM BP-11269) is preferable.
  • Each DMEM medium prepared above was inoculated with 10 8 cfu / ml of Lactobacillus delbrueckii subsp. Bulgaricus OLL1181 (FERM BP-11269) as a lactic acid bacterium at 37 ° C. for 3 hours. Cultured. Then, in the same manner as in Test 1, the concentration of acetic acid in the cultured medium was measured using HPLC. The result is shown in FIG. In addition, the number of lactic acid bacteria in each medium before and after the culture was calculated in the same manner as in Test 1 using the turbidity (absorbance at 650 nm) of each medium before and after the culture and a calibration curve prepared in advance.
  • acetic acid decreased by 3% by the addition of quercetin. Moreover, acetic acid increased by 54% by the addition of taxifolin. Moreover, acetic acid increased by 14% by the addition of phloretin. Moreover, acetic acid increased by 43% by addition of epigallocatechin gallate.
  • the organic acid production promoter of this embodiment it is possible to increase the amount of organic acid produced by these microorganisms regardless of the number (quantity) of bifidobacteria and lactic acid bacteria. It is.
  • the preventive and / or ameliorating agent for inflammatory bowel disease of this embodiment containing such an organic acid production promoter the growth of harmful bacteria is suppressed in the intestine, and the intestinal flora Through the improvement effect, it is possible to obtain an excellent preventive effect and / or improvement effect against inflammatory bowel disease.
  • the present invention is not limited to the above-described embodiments and examples, and various modifications can be made within the scope of the present invention.
  • quercetin, taxifolin, phloretin, epigallocatechin gallate, and procyanidin are used as the polyphenol in the above-described embodiments and examples, other polyphenols that exhibit the same effects as these may be used.
  • microorganisms other than the strains shown in the embodiments may be used as the bifidobacteria and lactic acid bacteria.
  • you may contain polyphenol, bifidobacteria, and lactic acid bacteria as an active ingredient combining 2nd embodiment and 3rd embodiment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention augmente l'efficacité de production d'acides organiques de bifidobactéries et de bactéries lactiques, indépendamment des nombres de ces bactéries bénéfiques. Le problème est résolu par un promoteur de production d'acides organiques pour stimuler la production d'acides organiques par l'utilisation de bifidobactéries et de bactéries lactiques contenant du polyphénol en tant que substance active. La quercétine, la taxifoline, la phlorétine, le gallate d'épigallocatéchine ou la procyanidine est de préférence utilisé en tant que polyphénol.
PCT/JP2015/006425 2014-12-26 2015-12-24 Promoteur de production d'acides organiques, et agent pour prévenir et/ou améliorer une maladie intestinale inflammatoire WO2016103699A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016565924A JP6810610B2 (ja) 2014-12-26 2015-12-24 有機酸の産生促進剤、並びに炎症性腸疾患の予防及び／又は改善剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-264242 2014-12-26
JP2014264242 2014-12-26

Publications (1)

Publication Number Publication Date
WO2016103699A1 true WO2016103699A1 (fr) 2016-06-30

Family

ID=56149757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/006425 WO2016103699A1 (fr) 2014-12-26 2015-12-24 Promoteur de production d'acides organiques, et agent pour prévenir et/ou améliorer une maladie intestinale inflammatoire

Country Status (3)

Country Link
JP (1) JP6810610B2 (fr)
TW (1) TW201636010A (fr)
WO (1) WO2016103699A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017086451A1 (fr) * 2015-11-18 2017-05-26 エバラ食品工業株式会社 Procédé de production d'un produit de fermentation solide de bactéries lactiques induisant et exprimant une capacité de survie inhérente des bactéries, et produit de fermentation solide de bactéries lactiques préparé par ledit procédé
JP2018087171A (ja) * 2016-11-29 2018-06-07 株式会社明治 交感神経活性化用組成物
JP2019043952A (ja) * 2017-09-06 2019-03-22 東洋精糖株式会社 腸内環境改善剤およびβ−グルクロニダーゼ活性阻害剤
JP2020150793A (ja) * 2019-03-18 2020-09-24 ビオフェルミン製薬株式会社 腸内有用菌の増殖及び有機酸産生増強剤

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06166618A (ja) * 1991-06-07 1994-06-14 Taiyo Kagaku Co Ltd 整腸用組成物
JP2006273852A (ja) * 2005-03-03 2006-10-12 Meiji Milk Prod Co Ltd ビフィズス菌を有効成分とするアレルギー予防および／または治療剤
JP2007217435A (ja) * 2007-06-01 2007-08-30 Kirin Holdings Co Ltd 酵母細胞壁画分からなる便秘の予防及び／又は症状改善剤
JP2008500032A (ja) * 2004-05-25 2008-01-10 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 経口および／または局所用組成物
JP2008195652A (ja) * 2007-02-13 2008-08-28 Ezaki Glico Co Ltd カカオ成分を含有する大腸炎抑制剤
JP2009084215A (ja) * 2007-09-28 2009-04-23 Nippon Paper Chemicals Co Ltd 炎症性腸疾患予防・治療剤
WO2010101175A1 (fr) * 2009-03-04 2010-09-10 明治乳業株式会社 Poudre lyophilisée de cellules microbiennes et son procédé de fabrication
WO2012033151A1 (fr) * 2010-09-09 2012-03-15 株式会社明治 Composition pour la prévention d'inflammations
JP2013147469A (ja) * 2012-01-20 2013-08-01 Calpis Co Ltd 腸内酪酸産生菌増加剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101409266B1 (ko) * 2011-11-24 2014-06-24 영남대학교 산학협력단 바이오필름 억제제 및 억제방법
CN102614278A (zh) * 2012-04-20 2012-08-01 江西天施康中药股份有限公司 一种肠炎宁制剂及其制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06166618A (ja) * 1991-06-07 1994-06-14 Taiyo Kagaku Co Ltd 整腸用組成物
JP2008500032A (ja) * 2004-05-25 2008-01-10 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 経口および／または局所用組成物
JP2006273852A (ja) * 2005-03-03 2006-10-12 Meiji Milk Prod Co Ltd ビフィズス菌を有効成分とするアレルギー予防および／または治療剤
JP2008195652A (ja) * 2007-02-13 2008-08-28 Ezaki Glico Co Ltd カカオ成分を含有する大腸炎抑制剤
JP2007217435A (ja) * 2007-06-01 2007-08-30 Kirin Holdings Co Ltd 酵母細胞壁画分からなる便秘の予防及び／又は症状改善剤
JP2009084215A (ja) * 2007-09-28 2009-04-23 Nippon Paper Chemicals Co Ltd 炎症性腸疾患予防・治療剤
WO2010101175A1 (fr) * 2009-03-04 2010-09-10 明治乳業株式会社 Poudre lyophilisée de cellules microbiennes et son procédé de fabrication
WO2012033151A1 (fr) * 2010-09-09 2012-03-15 株式会社明治 Composition pour la prévention d'inflammations
JP2013147469A (ja) * 2012-01-20 2013-08-01 Calpis Co Ltd 腸内酪酸産生菌増加剤

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CURIEL, J. A. ET AL.: "pH and dose-dependent effects of quercetin on the fermentation capacity of Lactobacillus plantarum", LWT - FOOD SCIENCE AND TECHNOLOGY, vol. 43, no. 6, 2010, pages 926 - 933, XP026984679 *
DODDA, D. ET AL.: "Protective effect of quercetin against acetic acid induced inflammatory bowel disease (IBD) like symptoms in rats: possible morphological and biochemical alterations", PHARMACOLOGICAL REPORTS, vol. 66, no. 1, February 2014 (2014-02-01), pages 169 - 173 *
FOGLIANO, V. ET AL.: "In vitro bioaccessibility and gut biotransformation of polyphenols present in the water-insoluble cocoa fraction", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 55, no. 1, 2011, pages S44 - S55 *
HUR, S. J. ET AL.: "Review of natural products actions on cytokines in inflammatory bowel disease", NUTRITION RESEARCH, vol. 32, no. 11, 2012, pages 801 - 816, XP002697231, DOI: doi:10.1016/j.nutres.2012.09.013 *
KAWABATA, K. ET AL.: "Effects of phytochemicals on in vitro anti-inflammatory activity of Bifidobacterium adolescentis", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 79, no. 5, May 2015 (2015-05-01), pages 799 - 807 *
KAWABATA, K. ET AL.: "Flavonols enhanced production of anti-inflammatory substance(s) by Bifidobacterium adolescentis: prebiotic actions of galangin,quercetin, and fisetin", BIOFACTORS, vol. 39, no. 4, 2013, pages 422 - 429 *
LEE, J. H. ET AL.: "Apple flavonoid phloretin inhibits Escherichia coli 0157:H7 biofilm formation and ameliorates colon inflammation in rats", INFECTION AND IMMUNITY, vol. 79, no. 12, 2011, pages 4819 - 4827 *
MOCHIZUKI, M. ET AL.: "Epigallocatechin-3- gallate reduces experimental colon injury in rats by regulating macrophage and mast cell", PHYTOTHERAPY RESEARCH, vol. 24, no. 1, 2010, pages S120 - S122 *
ZHANG, X. ET AL.: "Fermentation in vitro of EGCG, GCG and EGCG3''Me isolated from Oolong tea by human intestinal microbiota", FOOD RESEARCH INTERNATIONAL, vol. 54, no. 2, 2013, pages 1589 - 1595 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017086451A1 (fr) * 2015-11-18 2017-05-26 エバラ食品工業株式会社 Procédé de production d'un produit de fermentation solide de bactéries lactiques induisant et exprimant une capacité de survie inhérente des bactéries, et produit de fermentation solide de bactéries lactiques préparé par ledit procédé
JP2018087171A (ja) * 2016-11-29 2018-06-07 株式会社明治 交感神経活性化用組成物
US11147791B2 (en) 2016-11-29 2021-10-19 Meiji Co., Ltd. Composition for activating sympathetic nerve
JP2019043952A (ja) * 2017-09-06 2019-03-22 東洋精糖株式会社 腸内環境改善剤およびβ−グルクロニダーゼ活性阻害剤
JP7210193B2 (ja) 2017-09-06 2023-01-23 東洋精糖株式会社 腸内環境改善剤およびβ－グルクロニダーゼ活性阻害剤
JP2020150793A (ja) * 2019-03-18 2020-09-24 ビオフェルミン製薬株式会社 腸内有用菌の増殖及び有機酸産生増強剤
WO2020189228A1 (fr) * 2019-03-18 2020-09-24 ビオフェルミン製薬株式会社 Activateur de la croissance de bactéries intestinales bénéfiques et de production d'acide organique

Also Published As

Publication number Publication date
TW201636010A (zh) 2016-10-16
JPWO2016103699A1 (ja) 2017-10-05
JP6810610B2 (ja) 2021-01-06

Similar Documents

Publication Publication Date Title
Piekarska-Radzik et al. Mutual influence of polyphenols and Lactobacillus spp. bacteria in food: A review
Duda-Chodak et al. Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review
JP5923238B2 (ja) 迷走神経活性化剤
CA2787544C (fr) Composition probiotique a utiliser dans le traitement d'inflammation intestinale
WO2013084971A1 (fr) Stimulant du metabolisme des lipides et/ou du metabolisme du sucre contenant une bacterie d'acide lactique ou produit de traitement associe
Shipradeep et al. Development of probiotic candidate in combination with essential oils from medicinal plant and their effect on enteric pathogens: a review
JP2012510291A (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
JP6479768B2 (ja) 新規ラクトバチラス・パラカゼイ株
WO2021177526A1 (fr) Souche de lactobacillus reuteri l1071 dérivée du lait maternel présentant une excellente innocuité et une excellente adhésivité intestinale et composition comprenant la souche ou un produit cultivé de celle-ci
Bendali et al. In vitro and in vivo cholesterol lowering ability of Lactobacillus pentosus KF923750
WO2016103699A1 (fr) Promoteur de production d'acides organiques, et agent pour prévenir et/ou améliorer une maladie intestinale inflammatoire
KR101426275B1 (ko) 지방합성 억제 및 지방산화 촉진에 의한 체지방 감소 효능을 갖는 5종의 유산균 복합균주를 유효성분으로 함유하는 조성물
JP2010200611A (ja) 肥満予防又は改善剤
CA3183826A1 (fr) Compositions et procedes associes pour aider des animaux de compagnie souffrant de troubles gastro-intestinaux
KR102344838B1 (ko) 항균 및 항비만 활성을 갖는 락토바실러스 플란타룸 yg1102 균주 및 이의 용도
JP2019118281A (ja) ケフィア粒構成菌産生物
Stojanov et al. Interaction between silver fir (Abies alba) wood water extract and lactobacilli
US20230293607A1 (en) Lactobacillus formulations with improved stability and efficacy
JP5836928B2 (ja) 大腸におけるビフィズス菌の増加及び減少抑制剤
JP5950993B2 (ja) 迷走神経活性化剤
JP5544234B2 (ja) 歯周病菌生育抑制用組成物
KR20200065546A (ko) 와이셀라 시바리아 jw15 균주를 포함하는 세균성 장질환 예방, 치료 또는 개선용 조성물
Kwon et al. In-vitro prebiotic activity of grape seed flour highly rich in flavonoid and dietary fiber
KR20190077714A (ko) 항비만 효과를 갖는 락토바실러스 플란타룸 kc28 균주 및 이의 용도
KR20180040906A (ko) 질염 예방 및 치료용 폴리감마글루탐산 함유 조성물 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15872270

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016565924

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15872270

Country of ref document: EP

Kind code of ref document: A1